LAUSR

Prognosis and treatment options of hepatitis B virus‐related hepatocellular carcinoma (HBV‐HCC) are generally based on tumor burden and liver function. Yet, tumor growth and therapeutic resistance of HBV‐HCC are strongly influenced by intratumoral hypoxia and cells infiltrating the tumor microenvironment (TME). We, therefore, studied whether linking parameters associated with hypoxia and TME cells could have a better prediction of prognosis and therapeutic responses. Quantification of 109 hypoxia‐related genes and 64 TME cells was performed in 452 HBV‐HCC tumors. Prognostic hypoxia and TME cells signatures were determined based on Cox regression and meta‐analysis for generating the Hypoxia‐TME classifier. Thereafter, the prognosis, tumor, and immune characteristics as well as the benefit of therapies in Hypoxia‐TME defined subgroups were analyzed. Patients in the Hypoxialow/TMEhigh subgroup showed a better prognosis and therapeutic responses than any other subgroups, which can be well elucidated based on the differences in terms of immune‐related molecules, tumor somatic mutations, and cancer cellular signaling pathways. Notably, our analysis furthermore demonstrated the synergistic influence of hypoxia and TME on tumor metabolism and proliferation. Besides, the classifier allowed a further subdivision of patients with early‐ and late‐HCC stages. In addition, the Hypoxia‐TME classifier was validated in another independent HBV‐HCC cohort (n = 144) and several pan‐cancer cohorts. Overall, the Hypoxia‐TME classifier showed a pretreatment predictive value for prognosis and therapeutic responses, which might provide new directions for strategizing patients with optimal therapies.